Gill Heart and Vascular Institute, University of Kentucky, 326 Wethington Building, 900 South Limestone Street, Lexington, KY, 40536-0200, USA.
Am J Cardiovasc Drugs. 2018 Dec;18(6):427-440. doi: 10.1007/s40256-018-0292-1.
The history of digitalis is rich and interesting, with the first use usually attributed to William Withering and his study on the foxglove published in 1785. However, some knowledge of plants with digitalis-like effects used for congestive heart failure (CHF) was in evidence as early as Roman times. The active components of the foxglove (Digitalis purpurea and Digitalis lanata) are classified as cardiac glycosides or cardiotonic steroids and include the well-known digitalis leaf, digitoxin, and digoxin; ouabain is a rapid-acting glycoside usually obtained from Strophanthus gratus. These drugs are potent inhibitors of cellular membrane sodium-potassium adenosine triphosphatase (Na/K-ATPase). For most of the twentieth century, digitalis and its derivatives, especially digoxin, were the available standard of care for CHF. However, as the century closed, many doubts, especially regarding safety, were raised about their use as other treatments for CHF, such as decreasing the preload of the left ventricle, were developed. Careful attention is needed to maintain the serum digoxin level at ≤ 1.0 ng/ml because of the very narrow therapeutic window of the medication. Evidence for benefit exists for CHF with reduced ejection fraction (EF), also referred to as heart failure with reduced EF (HFrEF), especially when considering the combination of mortality, morbidity, and decreased hospitalizations. However, the major support for using digoxin is in atrial fibrillation (AF) with a rapid ventricular response when a rate control approach is planned. The strongest support of all for digoxin is for its use in rate control in AF in the presence of a marginal blood pressure, since all other rate control medications contribute to additional hypotension. In summary, these days, digoxin appears to be of most use in HFrEF and in AF with rapid ventricular response for rate control, especially when associated with hypotension. The valuable history of the foxglove continues; it has been modified but not relegated to the garden or the medical history book, as some would advocate.
洋地黄的历史丰富而有趣,其首次使用通常归因于威廉·威瑟林 (William Withering),他于 1785 年发表了有关毛地黄的研究。然而,早在罗马时代,就已经有一些关于具有洋地黄样作用的植物用于充血性心力衰竭 (CHF) 的知识。毛地黄(Digitalis purpurea 和 Digitalis lanata)的活性成分被归类为强心苷或强心甾类,包括众所周知的洋地黄叶、地高辛和 digoxin;哇巴因是一种快速作用的糖苷,通常从非洲夹竹桃中提取。这些药物是细胞膜钠钾三磷酸腺苷酶 (Na/K-ATPase) 的有效抑制剂。在 20 世纪的大部分时间里,洋地黄及其衍生物,尤其是 digoxin,是 CHF 的标准治疗方法。然而,随着世纪之交的到来,人们对其作为 CHF 其他治疗方法(例如降低左心室前负荷)的使用提出了许多质疑,尤其是安全性方面的质疑。由于药物的治疗窗非常狭窄,因此需要密切注意将血清地高辛水平维持在≤1.0ng/ml。对于射血分数降低的心力衰竭(EF),也称为射血分数降低的心力衰竭(HFrEF),有证据表明存在益处,特别是在考虑死亡率、发病率和住院率降低的情况下。然而,使用地高辛的主要依据是计划采用心率控制方法时伴有快速心室反应的心房颤动 (AF)。所有对地高辛的支持中最强的是在血压偏低时用于 AF 中的心率控制,因为所有其他的心率控制药物都会导致血压进一步降低。总之,如今,地高辛似乎在 HFrEF 和伴有快速心室反应的 AF 中用于心率控制最有用,尤其是在伴有低血压的情况下。洋地黄的宝贵历史仍在继续;它已经被修改,但并没有像有些人所主张的那样被降级为花园或医学史书。